Case of type 1 diabetes mellitus following interferon β-1a treatment for multiple sclerosis

Internal Medicine

Volumn 51, Issue 14, 2012, Pages 1875-1877

  Uonaga, Taeko ^a   Yoshida, Kenichi ^a   Harada, Takanari ^a   Shimodahira, Makiko ^a   Nakamura, Yoshio ^a  

^a Hyogo Prefectural Amagasaki Hospital   (Japan)

Author keywords

Interferon 1a; Multiple sclerosis; Type 1 diabetes mellitus

Indexed keywords

BETA1A INTERFERON; C PEPTIDE; C REACTIVE PROTEIN; GLUTAMATE DECARBOXYLASE ANTIBODY; HEMOGLOBIN A1C; HLA A24 ANTIGEN; HLA B ANTIGEN; HLA B54 ANTIGEN; HLA DRB1 ANTIGEN; INSULIN; INSULIN GLARGINE; INSULIN LISPRO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; DIABETIC KETOACIDOSIS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE SCLEROSIS; POLYDIPSIA; WEIGHT REDUCTION;

AUTOANTIBODIES; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; FEMALE; GLUTAMATE DECARBOXYLASE; HEMOGLOBIN A, GLYCOSYLATED; HLA ANTIGENS; HUMANS; INTERFERON-BETA; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 84864042082     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.51.7609     Document Type: Article

References (29)

1. Nagai Y, Ohsawa K, Ieki Y, Kobayashi K. Effect of interferon-beta on thyroid function in patients of chronic hepatitis C without preexisting autoimmune thyroid disease. Endocr J 43: 545-549, 1996.
2. Karino Y, Hige S, Matsushima T, Toyota J. Interstitial pneumonia induced by interferon therapy in type C hepatitis. Nihon Rinsho 52: 1905-1909, 1994 (in Japanese, Abstract in English).
3. Ohira M, Ito D, Shimizu T, Shibata M, Ohde H, Suzuki N. Retinopathy: an overlooked adverse effect of interferon-beta treatment of multiple sclerosis. Keio J Med 58: 54-56, 2009.
4. Condat B, Asselah T, Zanditenas D, et al. Fatal cardiomyopathy associated with pegylated interferon/ribavirin in a patient with chronic hepatitis C. Eur J Gastroenterol Hepatol 18: 287-289, 2006.
5. Khakoo AY, Halushka MK, Rame JE, Rodriguez ER, Kasper EK, Judge DP. Reversible cardiomyopathy caused by administration of interferon alpha. Nat Clin Pract Cardiovasc Med 2: 53-57, 2005.
6. Uehara E, Uesugi T, Tasaka T, et al. Reversible cardiomyopathy secondary to interferon-alpha in chronic myelogenous leukemia. Gan To Kagaku Ryoho 29: 317-321, 2002 (in Japanese, Abstract in English).
7. Morino Y, Hara K, Ushikoshi H, et al. Gamma-interferon-induced cardiomyopathy during treatment of renal cell carcinoma: a case report. J Cardiol 36: 49-57, 2000 (in Japanese, Abstract in English).
8. Chen J, Baig E, Fish EN. Diversity and relatedness among the type I interferons. J Interferon Cytokine Res 24: 687-698, 2004.
9. Tomer Y, Menconi F. Interferon induced thyroiditis. Best Pract Res Clin Endocrinol Metab 23: 703-712, 2009.
10. Pellicano R, Smedile A, Peyre S, et al. Autoimmune manifestations during interferon therapy in patients with chronic hepatitis C: the hepatologist's view. Minerva Gastroenterol Dietol 51: 55-61, 2005.
11. Selmi C, Lleo A, Zuin M, Podda M, Rossaro L, Gershwin ME. Interferon alpha and its contribution to autoimmunity. Curr Opin Investig Drugs 7: 451-456, 2006.
12. Vial T, Descotes J. Immune-mediated side-effects of cytokines in humans. Toxicology 105: 31-57, 1995.
13. Nakamura K, Kawasaki E, Abiru N, et al. Trajectories of anti-islet autoantibodies before development of type 1 diabetes in interferon-treated hepatitis C patients. Case reports and a literature review. Endocr J 57: 947-951, 2010.
14. Kado S, Miyamoto J, Komatsu N, et al. Type 1 diabetes mellitus caused by treatment with interferon-beta. Intern Med 39: 146-149, 2000.
15. Nakamura K, Kawasaki E, Imagawa A, et al. Type 1 diabetes and interferon therapy: a nationwide survey in Japan. Diabetes Care 34: 2084-2089, 2011.
16. Bach JF, Chatenoud L. Tolerance to islet autoantigens in type 1 diabetes. Annu Rev Immunol 19: 131-161, 2001.
17. Somoza N, Vargas F, Roura-Mir C, et al. Pancreas in recent onset insulin-dependent diabetes mellitus: changes in HLA, adhesion molecules and autoantigens, restricted T cell receptor V beta usage, and cytokine profile. J. Immunol 153: 1360-1377, 1994.
18. Foulis AK, Farquharson MA, Meager A. Immunoreactive alphainterferon in insulin-secreting beta cells in type 1 diabetes mellitus. Lancet 2: 1423-1427, 1987.
19. Huang X, Yuang J, Goddard A, et al. Interferon expression in the pancreases of patients with type I diabetes. Diabetes 44: 658-664, 1995.
20. Alba A, Puertas MC, Carrillo J, et al. IFN beta accelerates autoimmune type 1 diabetes in nonobese diabetic mice and breaks the tolerance to beta cells in nondiabetes-prone mice. J Immunol 173: 6667-6675, 2004.
21. Howson JM, Walker NM, Clayton D, Todd JA; Type 1 Diabetes Genetics Consortium. Confirmation of HLA class II independent type 1 diabetes associations in the major histocompatibility complex including HLA-B and HLA-A. Diabetes Obes Metab 11 (Suppl 1): 31-45, 2009.
22. Nejentsev S, Howson JM, Walker NM, et al. Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature 450: 887-892, 2007.
23. Kawasaki E, Matsuura N, Eguchi K. Type 1 diabetes in Japan. Diabetologia 49: 828-836, 2006.
24. Nakanishi K, Kobayashi T, Murase T, et al. Association of HLAA24 with complete beta-cell destruction in IDDM. Diabetes 42: 1086-1093, 1993.
25. Hamaguchi K, Kimura A, Seki N, et al. Analysis of tumor necrosis factor-ffpromoter polymorphism in type 1 diabetes: HLA-B and-DRB1 alleles are primarily associated with the disease in Japanese. Tissue Antigens 55: 10-16, 2000.
26. Leslie RD, Atkinson MA, Notkins AL. Autoantigens IA-2 and GAD in Type I (insulin-dependent) diabetes. Diabetologia 42: 3-14, 1999.
27. Handel AE, Handunnetthi L, Ebers GC, Ramagopalan SV. Type 1 diabetes mellitus and multiple sclerosis: common etiological features. Nat Rev Endocrinol 5: 655-664, 2009.
28. Nielsen NM, Westergaard T, Frisch M, et al. Type 1 diabetes and multiple sclerosis: a Danish population-based cohort study. Arch Neurol 63: 1001-1004, 2006.
29. Wandinger KP, Trillenberg P, Klüter H, Wessel K, Kirchner H. Clinical and molecular findings in multiple sclerosis patients with type 1 diabetes mellitus. J Clin Neurosci 6: 373-374, 1999.